Book a Meeting

Highly Galactosylated Anti-CD19 SGN-CD19A(Denintuzumab mafodotin), a Biobetter Antibody (CAT#: BioBet-GA-105ZP) Datasheet

Target
CD19
Isotype
Human Therapeutic Antibody
Description
Galactosylation of the IgG Fc region has been observed to modestly enhance C1q binding and ADCC in vitro in therapeutic antibodies. The Highly Galactosylated Anti-CD19 SGN-CD19A(Denintuzumab mafodotin), a Biobetter Antibody contains with a high level of galactosylation, and produced by the Fc engineering platform of Creative Biolabs.
Indication
Cancers
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 Molecule
Background
CD19 (CD19 Molecule) is a Protein Coding gene.
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers.
Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Alternative Names
CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID
UniProt ID
Cellular Localization
Plasma membrane
Genecards
Ensembl
OMIM
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Involvement in Disease
Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).
Related Pathways
As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signaling pathway activation and trigger b-cell response to antigen (PubMed: 2463100, PubMed: 1373518, PubMed: 16672701). Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Not needed in the early steps of bone marrow B cell differentiation (PubMed:9317126). Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges (PubMed: 2463100, PubMed: 1373518). Requires normal levels of serum immunoglobulins, and high-affinity antibodies produced upon antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701). 发送反馈 历史记录
Function
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Field of research
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Trade name
SGN-CD19A(Denintuzumab mafodotin)
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human Therapeutic Antibody
Antibody Clone
SGN-CD19A(Denintuzumab mafodotin)
Species Reactivity
Human
Description
Recombinant humanized antibody expressed in CHO binding to human CD19. SGN-CD19A(Denintuzumab mafodotin) is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.
Indication
Cancers

Cancers

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany